A comprehensive molecular analysis of muscle-invasive bladder cancer (MIBC) tumors has uncovered specific protein isoforms and signaling pathways associated with resistance to standard cisplatin-based chemotherapy, offering new potential strategies to guide treatment and improve patient outcomes. The study, published in Cell Reports Medicine by researchers at Baylor College of Medicine, identified cell signaling pathways that drive chemotherapy resistance , suggesting potential new methods for treating MIBC.

“One of our goals was to identify molecular markers in patient tumors that would help us predict which patients were most likely to benefit from chemotherapy and which ones might not,” said first co-author, Matthew V. Holt, PhD, a laboratory director at Baylor College of Medic

See Full Page